Covid-19 living Data

Vaccines for covid-19 patients

As part of the COVID-NMA initiative, we are identifying all randomized controlled trials (RCTs) of COVID-19 vaccine.

Below, you can access

A table with the general characteristics and risk of bias assessment for all RCTs identified.
A synthesis with forest plots and summary of findings table/evidence profile including phase 2-3 trials. For the vaccine (dose and schedule) evaluated in phase 2-3 trials, results available for the same vaccine (dose and schedule) in phase 1-2 trial will also be included in the synthesis.

Of note: For risk of bias assessment, we are considering the “effect of assignment to intervention” which might not be the analysis planned and reported by investigators. Consequently, when investigators planned to assess and report the “per-protocol” effect, the risk of bias for domain 2 may be evaluated as “some concerns”. We will contact investigators to obtain the results of the intent-to-treat analysis.

Treatment comparisons

We report below the forest plots for the main treatment comparisons.

Please choose a Treatment Comparison:

Inactivated virus

Non replicating viral vector

ChAdOx1 vs MenACWY (University of Oxford/AstraZeneca )

RNA based vaccine

BNT162b2 vs Placebo (BioNTech/Fosun Pharma/Pfizer )

mRNA-1273 vs Placebo (ModernaTX)

Last update: 22/01/2021

Trial	Type	Comparisons		Design	Participants	Sample size	Overall risk of bias	Full description
		Intervention 1	Intervention 2
NCT04470427 ModernaTX Baden LR, N Engl J Med, 2020 Full text FDA Briefing Full text Commentary	RNA based vaccine	mRNA-1273	Placebo	RCT Phase 3	Healthy adults with no known history of SARS-CoV-2 infection in 99 centers in the US	N=30351	Some concerns Details	Full description
NCT04368728 BioNTech/Fosun Pharma/Pfizer Polack FP,N Engl J Med,2020 Full text Commentary Commentary Commentary Commentary Commentary	RNA based vaccine	BNT162b2	Placebo	RCT Phase 2/3	Healthy SARS-CoV-2 DNA negative adults in multiple centres in Argentina, Brazil, Germany, South Africa, Turkey, and the USA	N=43548	Some concerns Details	Full description
NCT04368728 BioNTech SE, Pfizer Walsh E, N Engl J Med, 2020 Full text Commentary	RNA based vaccine	BNT162b1 10 mcg D1/21	Placebo	RCT Phase 1	Healthy SARS-CoV-2 serology/DNA negative adults in four centres in USA	N=195	Low Details	Full description
		BNT162b1 20 mcg D1/21	Placebo
		BNT162b1 30 mcg D1/21	Placebo
		BNT162b1 100 mcg D1/21	Placebo
		BNT162b2 10 mcg D1/21	Placebo
		BNT162b2 20 mcg D1/21	Placebo
		BNT162b2 30 mcg D1/21	Placebo

The link in the column "Overall risk of bias" provides access to a complete description of the assessment of each risk of bias domain with supports for judgement produced using the Revised Cochrane risk-of-bias tool for randomized trials RoB 2.

The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review. The link in the column "Full description" provides access to the general characteristics of the study.

We acknowledge that we may have been unable to extract some information from pre-prints, as they represent preliminary forms of scientific communication.